FDA Expedites ANDA Postapproval Manufacturing Changes

Acceleration Necessary Due To COVID-19 Impacts

 
• By Sue Sutter
  
To do list conceptual
Non-industry stakeholders shared their GDUFA III 'to do' list with FDA and generic drug companies • Source: Shutterstock

More from Generics

More from Products